PFN62958 is a useful peptide linker for synthesis of PSMA-617 (vipivotide tetraxetan), which is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA-617 originally was developed at the German Cancer Research Center and the Heidelberg University Hospital. ABX held the exclusive license to bring the treatment, which targets prostate-specific membrane antigen (PSMA), through early clinical development. is a tris(tert-butyl)-protected JUN68744 derivative.
PFN62958
Furin Substrate
Polymyxin B nonapeptide TFA
MC-Gly-Gly-Gly-PAB
MC-GGFG-PAB
MC-Gly-Gly-Phe-Gly-PAB-PNP
otbu-Glu(otbu)-urea-Lys(Ahx)
南昌探真生物技术有限公司
联系商家时请提及chemicalbook,有助于交易顺利完成!
探真-吴经理